Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer

Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer

The poor prognosis of pancreatic cancer requires the development of more effective therapy. CD147 expresses in pancreatic cancer with high incidence and has a crucial role in invasion and metastasis. We developed a fully human monoclonal antibody (059-053) with high affinity for CD147. Here we evalu...

Full description

Bibliographic Details
Main Authors: Aya Sugyo, Atsushi B. Tsuji, Hitomi Sudo, Mitsuru Koizumi, Yoshinori Ukai, Gene Kurosawa, Yoshikazu Kurosawa, Tsuneo Saga, Tatsuya Higashi
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:International Journal of Molecular Sciences
Subjects:
extracellular matrix metalloproteinase inducer
radioimmunotherapy
gemcitabine
combination therapy
pancreatic cancer
Online Access:http://www.mdpi.com/1422-0067/19/10/2979

Internet

http://www.mdpi.com/1422-0067/19/10/2979

Similar Items